Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap5.10B
Enterprise Value4.92B
Trailing P/E50.55
Forward P/E71.55
CORT
(NASDAQ)Corcept Therapeutics Incorporated
$42.49-- (--)
Loading... - Market loading
Corcept Therapeutics Incorporated (CORT) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)6.62
Forward Price/Sales5.87
Price/Book (mrq)7.78
Price/Tangible Book (mrq)7.78
Price/FCF (ttm)35.53
Price/OCF (ttm)35.47
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue6.47
EV/Earnings49.40
EV/EBITDA94.47
EV/EBIT75.07
EV/FCF34.72
Stock Price
Current price, 52-week range, and moving averages
Current Price$42.49
1-Day Change4.14%
52-Week High$91.00
52-Week Low$28.66
52-Week Change-54.33%
YTD Change9.90%
1-Year Change-49.91%
50-Day MA$37.74
200-Day MA$63.56
Avg Volume (30 day)1.50M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding119.99M
Book Value per Share$5.40
Net Cash per Share$1.00
FCF per Share$1.18
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$85.00
Target Upside/Downside100.05%
Analyst ConsensusBuy
Analyst Count3
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin98.30%
EBITDA Margin (ttm)6.84%
EBIT Margin (ttm)8.61%
Operating Margin (ttm)5.88%
Pretax Margin (ttm)8.73%
Profit Margin (ttm)13.09%
FCF Margin (ttm)18.62%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)15.38%
Return on Assets (ttm)11.91%
Return on Invested Capital (ttm)18.43%
Return on Capital Employed (ttm)9.78%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue761.41M
Gross Profit748.43M
Operating Income44.80M
Pretax Income66.46M
Net Income99.65M
EBITDA52.11M
EBIT65.57M
Diluted EPS$0.83
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow142.00M
Capital Expenditures211.00K
Free Cash Flow141.78M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth12.79%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)836.65M
Cash & Securities (mrq)120.50M
Net Cash (mrq)119.41M
Net Cash per Share$1.00
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)6.11M
Working Capital (mrq)319.38M
Total Equity (mrq)647.80M
Book Value per Share$5.40
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)2.92
Quick Ratio (mrq)2.85
Debt/Equity (mrq)0.01
Debt/EBITDA (ttm)0.12
Debt/FCF (ttm)0.04
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield1.98%
FCF Yield2.81%
Buyback Yield4.88%
Total Shareholder Yield4.88%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score18.71
Piotroski F-Score5/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$10.05
Graham Upside/Downside-76.06%
Frequently Asked Questions About Corcept Therapeutics Incorporated Statistics
What are the key financial metrics for CORT?
Corcept Therapeutics Incorporated (CORT) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is CORT's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Corcept Therapeutics Incorporated is overvalued or undervalued.
How do I read CORT's profitability ratios?
Corcept Therapeutics Incorporated's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do CORT's debt ratios indicate?
The financial health section shows Corcept Therapeutics Incorporated's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is CORT's dividend analysis?
The dividend section covers Corcept Therapeutics Incorporated's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.